Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

References

• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor mono-clonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009; 19:351–7.
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl 1):1–12.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y. International conference for the bone and joint decade. Rheumatic diseases at the dawn of the millennium. J Rheumatol. 2003;30(Suppl 67):1–2.
   Google Scholar
• Mugitani M. International conference for the bone and joint dec-ade. Bone and joint diseases around the world. Japan: strategy for rheumatic disease control. J Rheumatol. 2003;30(Suppl 67):47.
   Google Scholar
• Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, Fujiwara S. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis. 2005;64:1451–5.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, CHANGE Study Investigators. Clinical investiga-tion in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   Google Scholar
• Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8.
   PubMedGoogle Scholar
• HUMIRA (adalimumab) [prescribing information]. Pharmaceu-ticals and medical devices agency web site. http://www.info. pmda.go.jp/downfiles/ph/PDF/100159_3999426G1024_1_09.pdf. Accessed 22 November 2010 (in Japanese).
   Google Scholar
• Steinbrocker 0, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–62.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) Steering Committee. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Pharmaceuticals and medical devices agency web site. http://www.pmda.go.jp/ich/e/e2a_95_3_20e.pdf. Accessed 22 November 2010.
   Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DA528) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43: 1252–5.
   Google Scholar
• Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65: 889–94.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory dis-eases. Ann Rheum Dis. 2009;68:1863–9.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644–52.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.
   Google Scholar
• Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, etal. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52: 3403–12.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bac-terial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368–76.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitali-sation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339–44.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2–14.
   Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustia-nowski AP, British Society for Rheumatology Biologics Register, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011; 50:124–31.
   Google Scholar
• Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor (TNF) inhibitor; a report from the Registry of Japanese Rheu-matoid Arthritis Patients for Long-Term Safety (REAL). J Rheumatol. 2011;38:1258–64.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380–6.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associa-tions with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.
   Google Scholar
• Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074–81.
   Google Scholar
• Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford). 2010;49:82–90.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343–51.
   PubMed Web of Science ®Google Scholar
• Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399–407.
   Google Scholar